Browsing Wolfson Institute of Preventive Medicine by Author "Evangelou, N"
Now showing items 1-11 of 11
-
Anxiety affects the general well-being of people with ms during the COVID-19 pandemic more than the infection itself
Garjani, A; Hunter, R; Nicholas, R; Middleton, R; Tuite-Dalton, K; Coles, A; Dobson, R; Duddy, M; Ford, D; Hughes, S (2020-12) -
COVID-19 in people with MS: a large community-based study of the UK MS register
Garjani, A; Evangelou, N; Das Nair, R; Hunter, R; Tuite-Dalton, K; Coles, A; Dobson, R; Duddy, M; Ford, D; Hughes, S (2020-12) -
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies
Garjani, A; Middleton, RM; Hunter, R; Tuite-Dalton, KA; Coles, A; Dobson, R; Duddy, M; Hughes, S; Pearson, OR; Rog, D (Elsevier, 2021-05-05) -
Developing a clinical pathway to identify and manage cognitive problems in Multiple Sclerosis: Qualitative findings from patients, family members, charity volunteers, clinicians and healthcare commissioners
Smith, L; Elwick, H; Mhizha-Murira, JR; Topcu, G; Bale, C; Evangelou, N; Timmons, S; Leighton, P; das Nair, R (2021) -
The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multi-Methods Study
De Dios Perez, B; Pritchard, C; Powers, K; Nair, RD; Evangelou, N; Ford, H; Tallantyre, E; Dobson, R; Radford, K (Consortium of Multiple Sclerosis Centers, 2024-01-22) -
Memory rehabilitation for people with multiple sclerosis
Taylor, LA; Mhizha-Murira, JR; Smith, L; Potter, K-J; Wong, D; Evangelou, N; Lincoln, NB; das Nair, R (Wiley, 2021-10-18) -
Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre, EC; Dobson, R; Froud, JLJ; St John, FA; Anderson, VM; Arun, T; Buckley, L; Evangelou, N; Ford, HL; Galea, I (John Wiley & Sons Ltd, 2024-04-03)BACKGROUND AND PURPOSE: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on disease-modifying ... -
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
Tallantyre, EC; Scurr, MJ; Vickaryous, N; Richards, A; Anderson, V; Baker, D; Chance, R; Evangelou, N; George, K; Giovannoni, G (2022) -
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
Zaloum, SA; Wood, CH; Tank, P; Upcott, M; Vickaryous, N; Anderson, V; Baker, D; Chance, R; Evangelou, N; George, K (2023) -
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
Evangelou, N; Garjani, A; dasNair, R; Hunter, R; Tuite-Dalton, KA; Craig, EM; Rodgers, WJ; Coles, A; Dobson, R; Duddy, M (2020-08-27) -
Vitamin D levels in the UK MS population and COVID-19 susceptibility
Vickaryous, N; Garjani, A; Jacobs, B; Jitlal, M; Middleton, R; Das Nair, R; Tuite-Dalton, K; Hunter, R; Chandran, S; Macdougall, N (2020-12)